LungLifeAI Logo
Menu
close
LungLifeAI coupleLungLifeAI couple

Early detection

is key

dots

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally.  Using a minimally invasive blood draw, our LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules.

Watch the Latest Videos from LungLife AI

How Our LungLB®'s Test is Saving Lives

Watch Video

Early Detection

Watch Video

Creating a Different Future

Watch Video
1 2 3 … 6
View All Videos

One in 16 people in the US will be diagnosed with lung cancer in their lifetime—and in many cases when it’s too late. We believe our simple blood test may afford those at risk a much better outcome through early diagnosis.”

Paul Pagano | CEO, LungLife AI

Our purpose
is simple

To be a driving force

To Be a Driving Force

in the early detection of lung cancer.

To achieve our purpose, we are dedicated to working collaboratively with scientific and clinical partners.

To achieve our purpose, we are

dedicated to working collaboratively

 with scientific and clinical partners.

Our LungLB® Test

Our LungLB® Test

is a blood-based tool that has been developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer. The test is performed in our CLIA certified laboratory in Thousand Oaks, California. 

Order a Test

Featured News

April 17, 2025

Exclusive License and Distribution Agreement; Operational Update; Further on Proposed Cancellation of Admission to Trading on AIM   

 LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that it has entered into a conditional exclusive license and distribution agreement (the “Agreement”) for the commercial distribution of its LungLB® test (the “LungLB® test”) in the US with Circulogene Theranostics, Inc. a US liquid biopsy diagnostics company (“Circulogene” or the […]
• Read More
February 4, 2025

Operational and Funding Update and Proposed Cancellation from AIM

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, provides the following update.  As set out in the Operational Update on 19 November 2024, the Company had been actively engaged in discussions with several potential strategic partners. These discussions were aimed at identifying a partner that not only shares the Company’s […]
• Read More
1 2 3 … 37
LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
chevron-down